STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - $GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: $GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV
Rhea-AI Summary
Gilead Sciences (GILD) announces a new educational initiative to raise awareness about HIV prevention and treatment. The company will provide resources and support for at-risk communities, emphasizing the importance of early intervention and access to care. This initiative aligns with Gilead's commitment to public health and social responsibility, showcasing their leadership in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
News
Gilead Sciences Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
News
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Rhea-AI Summary
Gilead Sciences Inc. announces a $6 million grant program to support health equity for Australian and Canadian Indigenous communities. The program aims to address disparities in health outcomes related to HIV and viral hepatitis. Gilead is partnering with Indigenous-led organizations to fund culturally appropriate solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Rhea-AI Summary
Gilead Sciences receives European Commission approval for Trodelvy as a monotherapy for the treatment of HR-positive, HER2-negative breast cancer. The approval is based on the Phase 3 TROPiCS-02 study, which showed a statistically significant overall survival benefit and a reduction in disease progression or death. Trodelvy could replace standard chemotherapy and provide a new treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
News
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
partnership
News
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
Rhea-AI Summary
Gilead Sciences announced results from studies on Biktarvy as a treatment option for people with HIV. The studies included pregnant women, children, and adults with HIV/hepatitis B coinfection. In pregnant women, Biktarvy was well tolerated and maintained virologic suppression. In children, weight and lipid metabolism parameters improved with Biktarvy treatment. In adults with HIV/HBV coinfection, Biktarvy showed high rates of viral suppression and clinical benefits. Safety findings were similar between Biktarvy and other treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
News
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Rhea-AI Summary
Gilead Sciences Inc. has announced its largest commitment to health equity for Indigenous communities in Australia and Canada. The company will establish a $6 million USD grant program to address the disparities in health outcomes impacting Indigenous communities, particularly in relation to HIV and viral hepatitis. The funding will be divided equally between the two countries and invested over three years, supporting frontline organizations and initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
News
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced the discontinuation of the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility. The safety data aligns with the known magrolimab profile. Gilead recommends discontinuing treatment with magrolimab in MDS patients. Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications. Gilead expressed disappointment but emphasized the importance of patient well-being and the challenges in treating HR-MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
Stock GILD logo
Gilead Sciences Inc

NYSE:GILD

GILD Rankings

#146 Ranked by Market Cap
#2131 Ranked by Stock Gains
#681 Ranked by Dividends

GILD Stock Data

81.63B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
FOSTER CITY

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.